Skip to content

Magnesium-L-Threonate for Sleep Quality Post-Arthroplasty

Use of Magnesium-L-Threonate to Improve Subjective Sleep Quality After Total Joint Arthroplasties: Randomized Controlled Clinical Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06902285
Enrollment
64
Registered
2025-03-30
Start date
2025-04-21
Completion date
2027-07-01
Last updated
2026-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis, Sleep

Brief summary

The study team is conducting a study to see if Magnesium-L-Threonate (MgT) can help improve how well participants sleep and reduce pain after total joint replacement surgery

Interventions

Participants will receive a daily 145 mg pill by mouth 30 minutes before going to sleep

OTHERControl

Participants will receive two sugar pills daily by mouth 30 minutes before going to sleep

Sponsors

University of Miami
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing primary total knee or hip arthroplasty at the University of Miami Hospital * Patients \> 18 years of age * Subjects must be capable of providing informed consent * English or Spanish-speaking

Exclusion criteria

* Previous total joint arthroplasty at the surgical site * History of sleeping disorders, including narcolepsy, sleep apnea, insomnia, parasomnias, and restless leg syndrome. * History of Complex Regional Pain Syndrome in ipsilateral extremity * History of demyelinating disorder or neurologic deficit in the affected extremity * History of psychiatric disorders that could impact sleep, such as untreated depression, bipolar disorder, or schizophrenia. * Participants taking medications known to cause significant sedation or insomnia. * Pregnant or breastfeeding * Being treated for a diagnosis other than primary osteoarthritis (e.g. pelvic/femur fracture) * Patients with known substance use disorder within 6 months of surgery * Liver Failure, via clinical diagnosis or international normalized ratio greater than 1.5 or Prothrombin time greater than 40 * Chronic Kidney Disease or glomerular filtration rate less than 30 mL/min

Design outcomes

Primary

MeasureTime frameDescription
Change in Epsworth Sleepiness Score2 weeks, 4 weeks, 6 weeksScore ranging from 0-24 with higher scores indicating greater sleepiness.
Change in Pittsburgh Sleep Quality Index (PSQI)2 weeks, 4 weeks, 6 weeksThe total score has a value between 0-21 and a high total score demonstrates a poor quality of sleep. A total PSQI score which is ≤5 indicates "good sleep", and a score which is \>5 indicates "poor sleep

Secondary

MeasureTime frameDescription
Change in Morphine Milligram Equivalent Prescribed2 weeks, 4 weeks, 6 weeksMeasured in milligram equivalents
Patient-reported outcome measured by Knee Injury and Osteoarthritis Outcome Score6 weeksThe total score ranges from 0-100. Lowers scores indicate a healthier knee
Medication Compliance measured in number of days study medication taken6 weeksMedication compliance as measured by number of days taking study medication

Countries

United States

Contacts

CONTACTVictor H Hernandez, MD
vhh1@miami.edu305-689-5195
CONTACTJonathan Stern, MD
jms188@miami.edu305-689-5195
PRINCIPAL_INVESTIGATORVictor H Hernandez, MD

University of Miami

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 10, 2026